A link to this page has been copied to your clipboard.

https://www.gene.com/scientists/our-scientists/sarah-hymowitz

Paste this link in an email to share.

Ok

Scientists / Our Scientists

Sarah Hymowitz

Vice President & Principal Scientist, Protein Sciences

Postdoc Mentor

"I am motivated by the hope that our work may someday help patients. I am inspired by the talents and insights of my colleagues."

Years at Genentech

Publications

Awards & Honors

I started at Genentech as a postdoctoral fellow in 1999 studying the structure and function of members of the TNF super family of ligands and receptors. I was attracted to Genentech by the excellent science and the collaborative environment. In my current role, I have the privilege of working with colleagues on discovery, large molecule and small molecule projects. The Protein Science departments are responsible for the discovery of reagent and therapeutic antibodies. We also create biological reagents and data that further our understanding of the structure, function, and regulation of proteins of therapeutic interest and collaboratively enable the discovery of novel large molecule and small molecule therapeutics.

Featured Publication

Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2.

Cancer Cell. 2016 Apr 11;29(4):477-493.

Foster SA, Whalen DM, Özen A, Wongchenko MJ, Yin J, Yen I, Schaefer G, Mayfield JD, Chmielecki J, Stephens PJ, Albacker LA, Yan Y, Song K, Hatzivassiliou G, Eigenbrot C, Yu C, Shaw AS, Manning G, Skelton NJ, Hymowitz SG, Malek S.

View Abstract

My area of expertise is X-ray crystallography. We study the structure and interactions of macromolecules with ligands. These ligands can be receptors, small molecules or Fab fragments of antibodies. This information assists in the discovery of potential therapeutics and contributes to a better fundamental understanding of signaling events of importance to human disease.

Active research projects include kinase signaling complexes, receptor-ligand interactions, structural biology of ubiquitin signaling and antibody-antigen complexes.

Dimerization Induced by C-Terminal 14-3-3 Binding Is Sufficient for BRAF Kinase Activation

Biochemistry, ISSN: 15204995 00062960

Nicholas P. D. Liau; Avinashnarayan Venkatanarayan; John Quinn; Wilson Phung; Shiva Malek; Sarah Hymowitz; Jawahar Sudhamsu

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

A link to this page has been copied to your clipboard.

Sarah Hymowitz

Vice President & Principal Scientist, Protein Sciences

Featured Publication

Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2.

Portraits in Science

Strength in Numbers

Proteins: Seeing is Believing